

[Anatomic pathology selected abstracts](#)

written by CAP TODAY
April 16, 2024

April 2024—Fumarate hydratase-deficient renal cell carcinoma is a rare and distinct subtype of renal cancer caused by *FH* gene mutations. *FH* negativity and s-2-succinocysteine (2SC) positivity on IHC can be used to screen for *FH*-deficient renal cell carcinoma (RCC), but their sensitivity and specificity are imperfect. The expression of AKR1B10, an aldo-keto reductase that catalyzes cofactor-dependent oxidation-reduction reactions, in RCC is unclear. The authors compared AKR1B10, 2SC, and *FH* as diagnostic biomarkers for *FH*-deficient RCC. They included genetically confirmed *FH*-deficient RCCs (n=58), genetically confirmed TFE3 translocation RCCs (TFE3-tRCC; n=83), clear cell RCCs (n=188), chromophobe RCCs (n=128), and papillary RCCs (pRCC; n=97).



©2026 CAP TODAY, all rights reserved.

[Molecular pathology selected abstracts](#)

written by CAP TODAY
April 16, 2024

April 2024—Personalized medicine is revolutionizing cancer therapy, with targeted treatments customized to a person's cancer-specific mutational profile leading to substantially improved health outcomes. Personalized medicine can also be applied to cancer prevention for high-risk groups based on genetic predisposition or lifestyle factors. However, there is a significant gap in cancer research resulting from a lack of equitable representation of racial and ethnic groups in cancer databases. Most research data are derived from white patients in the United States and Europe, creating racial disparities in understanding cancer development and therapies. The underrepresentation of patients of African, Asian, and Native American descent in observational, translational, and clinical cancer studies is particularly notable.



Newsbytes

written by CAP TODAY
April 16, 2024

April 2024—Transitioning to digital pathology can seem complex and costly. And for some, but not all, laboratories, cost in particular can be a barrier to adoption. So how do you determine which camp your lab falls into? You calculate, according to Orly Ardon, PhD, director of digital pathology operations at Memorial Sloan Kettering Cancer Center.



©2026 CAP TODAY, all rights reserved.

Q&A column

written by CAP TODAY
April 16, 2024

April 2024

Q. Ordering clinicians are requesting that our laboratory flag abnormally high absolute neutrophil counts (ANC) on peritoneal fluids. We cannot find sources for reference ranges, but there is literature that states that a polymorphonuclear cell count greater than 250/ μ L is a reliable discriminatory test for bacterial peritonitis. We would like to use this as our reference and flag results with an ANC greater than 250 cells/ μ L as abnormally high. Is this acceptable? [Read answer.](#)

Q. How do you code fallopian tubes submitted for sterilization with a finding of a paratubal cyst? [Read answer.](#)



Letters

written by CAP TODAY

April 16, 2024

April 2024—The article “Test adds twists to lung disease diagnosis” (November 2023, page 1) virtually ignores the major problem of clinicians in the hospital thinking that it is perfectly okay to take specimens from patients in the hospital and send them directly to whatever laboratory they choose without input from the hospital’s laboratory administration or medical director. The laboratory medical director is legally responsible for approving the menu of laboratory tests to be performed in-house and all of the reference laboratories to be used.



©2026 CAP TODAY, all rights reserved.

Put It on the Board

written by CAP TODAY

April 16, 2024

April 2024—Member organizations of the Enduring Consensus Cervical Cancer Screening and Management Guidelines effort released in March their recommendations for the use of p16/Ki-67 dual stain for managing individuals who test positive for HPV.



©2026 CAP TODAY, all rights reserved.

Roche CDx to ID patients eligible for Enhertu gets CE mark

written by CAP TODAY
April 16, 2024

April 15, 2024—Roche announced it obtained the CE mark for its Ventana HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu (trastuzumab deruxtecan) may be considered as a targeted treatment.



©2026 CAP TODAY, all rights reserved.

FDA clears Pathfast POC hs-cTnI test

written by CAP TODAY
April 16, 2024

April 12, 2024—Polymedco announced FDA 510(k) clearance of the Pathfast hs-cTnI-II, a high-sensitivity cardiac troponin assay for the diagnosis of myocardial infarction at the point of care.



©2026 CAP TODAY, all rights reserved.

BYG4lab opens U.S. subsidiary in Chicago

written by CAP TODAY

April 16, 2024

April 12, 2024—BYG4lab Group has opened its U.S subsidiary, BYG4lab, in Chicago and appointed Tim Bickley, MLS(ASCP), MBA, CPHIMS, vice president of sales for the U.S. market.



©2026 CAP TODAY, all rights reserved.

Bio-Rad expands availability of Unity Next Peer QC

written by CAP TODAY

April 16, 2024

April 11, 2024—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software in Europe, the Middle East, and Africa.



©2026 CAP TODAY, all rights reserved.